细颗粒物通过DNMT3A介导的GPX4DNA甲基化调节加剧儿童喘
Xiaolu Wu1,2, Liangzhe Dai3, Ran Li4,5
1Department of Child Health Care, Women's Hospital of Nanjing Medical University, Nanjing Women and Children's Healthcare Hospital, Nanjing, China.
Scientific reports
|January 16, 2026
概括
细颗粒物 (PM2.5) 暴露会通过触发细胞死亡途径铁亡,加剧儿童喘. 这通过PM2.5诱导的GPX4的DNA甲基化发生,GPX4是一个关键的调节器,突出了新的治疗标.
科学领域:
- 环境健康 环境健康
- 分子生物学分子生物学
- 儿科肺病学 儿科肺病学
背景情况:
- 细颗粒物 (PM2.5) 是儿童喘恶化的已知危险因素.
- 连接PM2.5暴露与喘病原体的精确生物机制在很大程度上仍未定义.
研究的目的:
- 阐明PM2.5暴露加重儿童喘的分子机制.
- 调查铁和DNA甲基化在PM2.5引起的喘恶化中的作用.
主要方法:
- 在儿科模型中研究了PM2.5暴露对炎症细胞透和喘严重性的影响.
- 分析了GPX4的表达,反应性氧物种 (ROS),甲 (MDA) 和线粒体膜潜力的表达.
- 研究了DNMT3A的作用,GPX4促进体的DNA甲基化,以及它与喘患者的炎症标志物 (IL-6/8) 的相关性.
主要成果:
- 暴露于PM2.5诱导炎症细胞透,并通过依赖铁亡的途径恶化儿童喘.
- 过度表达GPX4可以抵消PM2.5引起的氧化应激和炎症.
- 暴露于PM2.5增加了DNMT3A,导致GPX4促进剂高甲基化,减少GPX4表达和铁死.
- 在儿童喘患者中,GPX4 DNA甲基化水平与IL-6/8水平相关.
结论:
- 在儿童喘的恶化中,PM2.5暴露,DNA甲基化和铁死是关键的相互联系.
- 针对GPX4甲基化提供了PM2.5相关的儿科喘的潜在治疗策略.
相关概念视频
Asthma: Pathogenesis and Management
1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
Asthma-I: Introduction
3.4K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.4K
Asthma-II: Pathophysiology and Classification
4.1K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.1K
Antiasthma Drugs: Leukotriene Modifiers
1.8K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.8K
Asthma-IV: Diagnostic and Management
3.1K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K


